CHNC China Infrastructure Construct

CHNC Announces to Its Allies the Rebranding and Name Change to Cannabis Bioscience International Holdings

CHNC Announces to Its Allies the Rebranding and Name Change to Cannabis Bioscience International Holdings

HOUSTON, TX, April 24, 2023 (GLOBE NEWSWIRE) -- via -- CBIH, previously known as CHNC, and trading under the ticker symbol CHNC, today unveiled the rebranding of its identity, including a new logo as part of its strategy to better reflect CBIH’s focus, medical purpose, and vision for the future.

Starting today, the company has officially begun the process of changing all its digital content, including old logos, websites, videos, advertising, products, and marketing descriptions. This implicates communication with educational and pharmaceutical partners, allies, and e-commerce distributors around the world. By the end of July, the company will strive to have finished the process.

"With a clear goal of helping patients and being part of the development of medicine, we visualized our company as an infinite world where the points need to be connected; nature should connect with science, people should connect with medicine, and business could be connected to all of these points. The rebranding of our firm is rooted in our company’s heritage, as well our new logo better reflects our focus on the near future of medicine," says CBIH’s Research Director Doctor Jennifer Salguero, Ph.D. in Science, University of São Paulo, Brazil.

This rebrand marks a major milestone for our operations, to dispel doubts concerning the location and business of the company, which works with clinical trials, sleep studies, and cannabis education from its office in Houston, Texas. In addition, CBIH´s management wishes to reassure its students, clients, partners, and distributors that these changes will not represent any inconveniences. Thus, our company unequivocally reaffirms to continue to invest the time, human resources, and investment dollars needed to improve the quality of life of thousands of people by continuing to create non-traditional medicine in a traditional world.

To learn more visit:

For more information contact us at:

817/528-2475 for English

214/733-0868 for Spanish



EN
24/04/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on China Infrastructure Construct

 PRESS RELEASE

Brian Cuban to Represent CBIH in DEA Hearings on Marijuana Reclassific...

Brian Cuban to Represent CBIH in DEA Hearings on Marijuana Reclassification HOUSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- CBIH is proud to announce that Brian Cuban, Esq., a distinguished attorney, best-selling author, mental health advocate, and esteemed member of our Advisory Board, has officially joined the Reclassification Team. Mr. Cuban will play a crucial role in representing CBIH at the upcoming DEA hearings on marijuana rescheduling. Brian Cuban, the younger brother of entrepreneur Mark Cuban, brings a unique combination of personal recovery experience and professional advocacy to ...

 PRESS RELEASE

Cannabis Bioscience International Holdings (CBIH) Announces Partnershi...

Cannabis Bioscience International Holdings (CBIH) Announces Partnership with Stephen Gould for Manufacturing and Distribution of Medical Products HOUSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (OTCMKTS: CBIH) is thrilled to announce a groundbreaking partnership with Stephen Gould, marking a monumental step forward in the manufacturing and distribution of CBIH’s advanced medical product line. This collaboration represents a shared commitment to excellence and innovation in the healthcare industry. Stephen Gould, a company with a remarkable presence...

 PRESS RELEASE

CBIH Files Petition to Include Alexis Bortell as Witness in DEA Resche...

CBIH Files Petition to Include Alexis Bortell as Witness in DEA Rescheduling Hearing HOUSTON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (CBIH) continues its unwavering advocacy for cannabis as a legitimate medicine by formally petitioning to have Ms. Alexis Bortell, long-time cannabis advocate and patient, to serve as a witness in the upcoming DEA hearing on marijuana rescheduling. Alexis Bortell has been a leading voice in the fight for medical cannabis access since being diagnosed with intractable epilepsy at the age of seven. After enduring years...

 PRESS RELEASE

A Letter from the Desk of CBIH

A Letter from the Desk of CBIH HOUSTON, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings CEO Dante Picazo Addresses Cannabis Reclassification and DEA Hearings Dear Community, On Monday, December 2, I had the honor of representing Cannabis Bioscience International Holdings (CBIH) at the DEA Hearing Docket No. 1362 and Hearing Docket No. 24-44, focused on the reclassification of cannabis. Being chosen to speak on behalf of not only our company but also medicine, science, and patients is a privilege and a profound responsibility. CBIH remains committed to activ...

 PRESS RELEASE

CBIH Advocates for Cannabis Policy Reform at DEA Reclassification Hear...

CBIH Advocates for Cannabis Policy Reform at DEA Reclassification Hearing HOUSTON, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (OTCMKTS: CBIH) proudly announces its active participation in today’s DEA meaningful hearing on cannabis reclassification. Representing CBIH at this critical event in Arlington, Virginia, is Dante Picazo, the company’s esteemed Director and CEO, bringing years of expertise and leadership in the medical cannabis industry to Docket No. 1362, Hearing Docket No. 24-44. Mr. Picazo has presented a comprehensive 78-page statement that un...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch